​

Halozyme Therapeutics Ownership | Who Owns Halozyme Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Halozyme Therapeutics Ownership Summary

Halozyme Therapeutics is owned by 53.28% institutional investors, 1.14% insiders, and 45.59% retail investors. Blackrock is the largest institutional shareholder, holding 13.88% of HALO shares. iShares Core S&P Mid-Cap ETF is the top mutual fund, with 3.35% of its assets in Halozyme Therapeutics shares.

HALO Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockHalozyme Therapeutics53.28%1.14%45.59%
SectorHealthcare Stocks 232.86%10.65%-143.51%
IndustryBiotech Stocks 382.13%10.41%-292.54%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock17.62M13.88%$922.58M
Blackrock funding, inc. /de13.15M11.22%$885.25M
Vanguard group11.57M9.87%$778.45M
State street5.02M4.14%$368.11M
Arrowstreet capital, limited partnership3.29M2.71%$241.34M
Invesco3.25M2.67%$238.04M
Morgan stanley2.66M2.27%$178.90M
William blair investment management2.53M2.11%$163.25M
Geode capital management2.43M2.08%$163.78M
Snyder capital management l p2.40M2.05%$161.47M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Koa wealth management93.82K4.38%$6.06M
Cutter capital management, lp120.00K3.33%$7.66M
Snyder capital management l p2.40M3.01%$161.47M
Panoramic capital89.43K2.95%$6.56M
Steamboat capital partners142.58K2.72%$10.46M
2xideas158.82K2.46%$11.65M
South street advisors231.76K2.19%$15.60M
Future fund95.12K2.16%$6.15M
Bernzott capital advisors68.28K2.11%$4.41M
Mizuho markets americas1.27M1.65%$85.38M

Top Buyers

HolderShares% AssetsChange
Norges bank1.90M0.01%1.90M
Voloridge investment management1.06M0.26%1.06M
Mizuho markets americas1.27M1.65%926.53K
Morgan stanley2.66M0.01%920.70K
Two sigma investments, lp1.32M0.14%876.09K

Top Sellers

HolderShares% AssetsChange
Dld asset management, lp---30.00M
Macquarie group---1.55M
Frontier capital management---1.27M
Pacer advisors---937.29K
State street5.02M0.01%-915.84K

New Positions

HolderShares% AssetsChangeValue
Norges bank1.90M0.01%1.90M$128.20M
Voloridge investment management1.06M0.26%1.06M$77.59M
Vanguard fiduciary trust747.36K0.01%747.36K$48.30M
Bridgewater associates, lp487.08K0.14%487.08K$35.72M
Hotchkis & wiley capital management134.63K0.03%134.63K$9.87M

Sold Out

HolderChange
Total investment management-1.00
Nemes rush group-2.00
Ross\johnson & associates-4.00
Harbor investment advisory-4.00
Raleigh capital management-6.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025371-39.58%62,451,323-58.49%530.35%186-37.79%135-43.04%
Sep 30, 2025351-37.21%58,910,289-54.67%480.42%159-40.67%146-31.78%
Jun 30, 2025552-1.08%129,712,8686.64%1061.10%263-16.51%21229.27%
Mar 31, 202515-97.10%5,085,362-95.89%40.04%6-97.75%4-97.75%
Dec 31, 2024292-43.41%70,690,093-43.61%550.57%130-52.38%114-30.91%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Mid-Cap ETF3.97M3.35%-2.00K
Vanguard US Total Market Shares ETF4.03M3.27%3.36K
Vanguard Total Stock Mkt Idx Inv3.74M3.15%29.64K
iShares Russell 2000 ETF3.13M2.54%-
Vanguard Small Cap Index2.72M2.30%53.68K
Aviva Investors GlConvtAbsRet I USD Acc2.74M2.16%2.74M
SPDR® S&P Biotech ETF2.18M1.86%4.86K
Delaware Small Cap Core I1.74M1.37%-10.77K
Vanguard Small Cap Growth Index Inv1.52M1.29%41.89K
State Street® SPDR® S&P® Biotech ETF1.42M1.20%-14.05K

Recent Insider Transactions

DateNameRoleActivityValue
May 01, 2026Connaughton Bernadette-Sell$103.16K
Apr 06, 2026Torley Helen PRESIDENT AND CEOSell$262.46K
Apr 06, 2026Torley Helen PRESIDENT AND CEOSell$372.52K
Apr 01, 2026Torley Helen PRESIDENT AND CEOSell$1.24M
Apr 02, 2026Torley Helen PRESIDENT AND CEOSell$1.01M

Insider Transactions Trends

DateBuySell
2027 Q1--
2026 Q1--
2025 Q4-13
2025 Q3-27
2025 Q2-7

HALO Ownership FAQ

Who Owns Halozyme Therapeutics?

Halozyme Therapeutics shareholders are primarily institutional investors at 53.28%, followed by 1.14% insiders and 45.58% retail investors. The average institutional ownership in Halozyme Therapeutics's industry, Biotech Stocks , is 382.13%, which Halozyme Therapeutics falls below.

Who owns the most shares of Halozyme Therapeutics?

Halozyme Therapeutics’s largest shareholders are Blackrock (17.62M shares, 13.88%), Blackrock funding, inc. /de (13.15M shares, 11.22%), and Vanguard group (11.57M shares, 9.87%). Together, they hold 34.97% of Halozyme Therapeutics’s total shares outstanding.

Does Blackrock own Halozyme Therapeutics?

Yes, BlackRock owns 13.88% of Halozyme Therapeutics, totaling 17.62M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 922.58M$. In the last quarter, BlackRock decreased its holdings by -622K shares, a -3.41% change.

Who is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested?

Koa wealth management is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.38% of its assets in 93.82K Halozyme Therapeutics shares, valued at 6.06M$.

Who is the top mutual fund holder of Halozyme Therapeutics shares?

iShares Core S&P Mid-Cap ETF is the top mutual fund holder of Halozyme Therapeutics shares, with 3.35% of its total shares outstanding invested in 3.97M Halozyme Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools